Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2024-06-13 DOI:10.1016/j.diabres.2024.111744

Abdul Rahaman Shaik , Sunil Kohli , Divya Vohora

{"title":"Bone effects of metformin monotherapy and its combination with teneligliptin: A 12-week follow-up study in patients with type 2 diabetes mellitus","authors":"Abdul Rahaman Shaik , Sunil Kohli , Divya Vohora","doi":"10.1016/j.diabres.2024.111744","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>The skeletal effects of metformin monotherapy and in combination with teneligliptin are not well illustrated in patients with T2DM. To address this, we conducted an observational study to evaluate the effect of these oral hypoglycemic agents on bone turnover markers.</p></div><div><h3>Methods</h3><p>We recruited patients with T2DM and first-ever prescribed metformin monotherapy or metformin combined with teneligliptin from a tertiary care teaching hospital in New Delhi, North India. Both bone formation and resorption markers, IL-6 and PTD, were estimated along with glycated hemoglobin at baseline and 12 weeks.</p></div><div><h3>Results</h3><p>In both groups, hbA1c levels decreased significantly from baseline to 12 weeks. In the metformin-treated group, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, BAP, or OPG at 12 weeks from baseline. In the metformin + teneligliptin group, BAP, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, or OPG after 12 weeks from baseline.</p></div><div><h3>Conclusions</h3><p>The positive bone outcome of metformin or teneligliptin was linked to bone resorption rather than bone formation and was independent of changes in HbA1c or PTD. However, these results must be confirmed with well-designed RCTs with more extended follow-up periods.</p></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822724006545","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

The skeletal effects of metformin monotherapy and in combination with teneligliptin are not well illustrated in patients with T2DM. To address this, we conducted an observational study to evaluate the effect of these oral hypoglycemic agents on bone turnover markers.

Methods

We recruited patients with T2DM and first-ever prescribed metformin monotherapy or metformin combined with teneligliptin from a tertiary care teaching hospital in New Delhi, North India. Both bone formation and resorption markers, IL-6 and PTD, were estimated along with glycated hemoglobin at baseline and 12 weeks.

Results

In both groups, hbA1c levels decreased significantly from baseline to 12 weeks. In the metformin-treated group, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, BAP, or OPG at 12 weeks from baseline. In the metformin + teneligliptin group, BAP, β-CTX, sRANKL, IL-6, and PTD decreased significantly, and no significant changes were observed in P1NP, OC, or OPG after 12 weeks from baseline.

Conclusions

The positive bone outcome of metformin or teneligliptin was linked to bone resorption rather than bone formation and was independent of changes in HbA1c or PTD. However, these results must be confirmed with well-designed RCTs with more extended follow-up periods.

查看原文本刊更多论文

二甲双胍单一疗法及其与替尼列汀联合疗法对骨骼的影响：对 2 型糖尿病患者进行为期 12 周的随访研究。

目的：二甲双胍单药治疗以及与替尼列汀联合治疗对 T2DM 患者骨骼的影响尚未得到很好的说明。为此，我们开展了一项观察性研究，以评估这些口服降糖药对骨转换标志物的影响：我们从印度北部新德里的一家三级医疗教学医院招募了首次接受二甲双胍单药治疗或二甲双胍联合替格列汀治疗的 T2DM 患者。在基线和 12 周时，对骨形成和骨吸收标志物 IL-6 和 PTD 以及糖化血红蛋白进行了评估：结果：两组患者的 hbA1c 水平从基线到 12 周均显著下降。在二甲双胍治疗组中，β-CTX、sRANKL、IL-6 和 PTD 均有明显下降，而 P1NP、OT、BAP 或 OPG 在 12 周时与基线相比无明显变化。二甲双胍+替格列汀组的BAP、β-CTX、sRANKL、IL-6和PTD明显下降，而P1NP、OT或OPG在基线12周后无明显变化：结论：二甲双胍或替尼列汀对骨骼的积极作用与骨吸收而非骨形成有关，且与 HbA1c 或 PTD 的变化无关。然而，这些结果必须通过设计良好、随访时间更长的 RCT 得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.